No CrossRef data available.
Depressive Illness and the Possibilities of Somatic Antidepressant Treatment
Published online by Cambridge University Press: 10 March 2009
Abstract
Depression constitutes a considerable mental health problem. Depression is too often unrecognized or unproperly treated, which causes distress, social impairment, and increased risk of mortality for the individual, and large costs for society. However, several efficient treatment modalities and strategies exist. Different somatic antidepressant treatments for short- and long-term therapy and their respective quality-of-life and economic aspects will be presented and discussed.
- Type
- Special Section: The Assessment of Psychiatry
- Information
- International Journal of Technology Assessment in Health Care , Volume 12 , Issue 4 , Fall 1996 , pp. 554 - 572
- Copyright
- Copyright © Cambridge University Press 1996
References
REFERENCES
1.Abou-Saleh, M. T.Who responds to prophylactic lithium therapy? British Journal of Psychiatry, 1993, 163(suppl. 21), 20–26.Google Scholar
2.Abrams, R.Electroconvulsive therapy, 2nd ed.New York: Oxford University Press, 1992.Google ScholarPubMed
3.American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed.Washington, DC: American Psychiatric Association, 1987.Google Scholar
4.American Psychiatric Association. Practice guideline for major depressive disorder in adults. American Journal of Psychiatry, 1993, 150(suppl.), 1–26.Google Scholar
5.American Psychiatric Association Task Force on Electroconvulsive Therapy. The practice of electroconvulsive therapy. Washington DC: APA, 1990.Google Scholar
6.Anderson, I. M., & Tomenson, B. M.Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis. British Medical Journal, 1995, 310, 1433–38.CrossRefGoogle ScholarPubMed
7.Angst, J.The epidemiology of depressive disorders. European Neuropsychopharmacology, 1995, 5(suppl.), 95–98.CrossRefGoogle ScholarPubMed
8.Asberg, M., & Mårtensson, B.Serotonin selective antidepressant drugs: Past, present, future. Clinical Neuropharmacology. 1993, 16(suppl 3), S32–44.Google Scholar
9.Asgård, U., Nordström, P., & Råbäck, G.Birth cohort analysis of changing suicide risk by sex and age in Sweden 1952 to 1981. Ada Psychiatrica Scandinavica, 1987, 76, 456–63.Google Scholar
10.Ayd, F. J.The early history of modern psychopharmacology. Neuropsychopharmacology, 1991, 5, 71–84.Google ScholarPubMed
11.Barden, N., Reul, J. M. H. M., & Holsboer, F.Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends in Neurosciences, 1995, 18, 6–11.CrossRefGoogle ScholarPubMed
12.Black, D. W., Winokur, G., Mohandoss, E., et al. Does treatment influence mortality in depressives? A follow-up of 1076 patients with major affective disorders. Annals of Clinical Psychiatry, 1989, 1, 165–73.Google Scholar
13.Blackwell, B.Hypertensive crisis due to monoamine oxidase inhibitors. Lancet, 1963, ii, 849–51.Google Scholar
14.Boissel, J.-P., Blanschard, J., Panak, E., et al. Considerations for the meta-analysis of randomized clinical trials. Controlled Clinical Trials, 1989, 10, 254–81.Google Scholar
15.Brown, G. W., Harris, T. O, & Hepworth, C.Life events and endogenous depression: A puzzle reexamined. Archives of General Psychiatry, 1994, 51, 525–34.CrossRefGoogle ScholarPubMed
16.Brown, G. W., & Moran, P.Clinical and psychosocial origins of chronic depressive episodes, I: A community survey. British Journal of Psychiatry, 1994, 165, 447–56.Google Scholar
17.Coppen, A., Standish-Barry, H., Bailey, J., et al. Does lithium reduce the mortality of recurrent mood disorders? Journal of Affective Disorders, 1991, 23, 1–7.CrossRefGoogle ScholarPubMed
18.Corruble, E., & Puech, A. J.How to improve the risk-benefit ratio of antidepressants. International Clinical Psychopharmacology, 1993, 8, 237–41.Google Scholar
19.Cowen, P. J., Power, A. C., Ware, C. J., & Anderson, I. M.5-HTIA receptor sensitivity in major depression: A neuroendocrine study with buspirone. British Journal of Psychiatry, 1994, 164, 372–79.Google Scholar
20.Cross-National Collaborative Group. The changing rates of depression: Cross-national comparisons. Journal of the American Medical Association, 1992, 268, 3099–105.Google Scholar
21.Danish University Antidepressant Group. Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology, 1986, 90, 131–38.Google Scholar
22.Danish University Antidepressant Group. Paroxetine: A selective reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders, 1990, 18, 289–99.Google Scholar
23.Davis, J. M. Antidepressant drugs. In Kaplan, M. I. & Sadock, B. J. (eds.) Comprehensive textbook of psychiatry. Baltimore: Williams & Wilkins, 1985, 1534–35.Google Scholar
24.Davis, M.Hepatotoxicity of antidepressants. International Clinical Psychopharmacology, 1991, 6, 97–103.CrossRefGoogle ScholarPubMed
25.Deakin, J. F. W.A review of clinical efficacy of 5-HT1A agonists in anxiety and depression. Journal of Psychopharmacology, 1993, 7, 283–89.Google Scholar
26.d'Elia, G. Comparison of electroconvulsive therapy with unilateral and bilateral stimulation, III: Anterograde amnesia. Acta Psychiatrica Scandinavica, 1970, 46(suppl. 215), 44–60.Google Scholar
27.Devanand, D. P., & Sackeim, H. A. Electroconvulsive therapy: Efficacy, side effects and mechanisms of action. In Pohl, R. & Gershon, S. (eds.), The biological basis of psychiatric treatment: Progress in basic and clinical pharmacology, vol. 3. Basel: Karger 1990, 170–210.Google Scholar
28.De Vry, J.5-HTIA receptor agonists: Recent developments and controversial issues. Psychopharmacology, 1995, 121, 1–26.CrossRefGoogle Scholar
29.Dubovsky, S. L.Beyond the serotonin reuptake inhibitors: Rationales for the development of new serotonergic agents. Journal of Clinical Psychiatry, 1994, 55(suppl. 2), 34–44.Google Scholar
30.Edwards, J. G., Inman, W. H., Wilton, L., & Pearce, G. L.Prescription-event monitoring of 10401 patients treated with fluvoxamine. British Journal of Psychiatry, 1994, 164, 387–95.Google Scholar
31.Edwards, J. G.Suicide and antidepressants: Controversies on prevention, provocation, and self poisoning continue. British Medical Journal, 1995, 310, 205–06.Google Scholar
32.Ferrier, I. N.Comparisons of clinical efficay. British Journal of Psychiatry, 1993, 163(suppl. 20), 25–28.CrossRefGoogle Scholar
33.Fink, M., & Ottosson, J.-O.A theory of convulsive therapy in endogenous depression: Significance of hypothalamic functions. Psychiatry Research, 1980, 2, 49–61.Google Scholar
34.Frank, E., Anderson, B., Reynolds, C. F. III, et al. Life events and the research diagnostic criteria endogenous subtype: A confirmation of the distinction using the Bedford College methods. Archives of General Psychiatry, 1994, 51, 519–24.CrossRefGoogle ScholarPubMed
36.Ghadirian, A. M., Engelsmann, F., Dhar, V., et al. The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biological Psychiatry, 1995, 37, 369–75.Google Scholar
37.Gibbons, R. D., Clark, D. C., & Kupfer, D. J.Exactly what does the Hamilton depression rating scale measure? Journal of Psychiatric Research, 1993, 27, 259–73.Google Scholar
38.Gitlin, M. J.Lithium-induced renal insufficiency. Journal of Clinical Psychopharmacology, 1993, 13, 276–79.Google Scholar
39.Glue, P., Christensen, P., Lolk, A., et al. Moclobemide: A reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders, 1993, 28, 105–16.Google Scholar
40.Goodwin, F. K., & Jamison, K. R.Manic-depressive illness. New York: Oxford University Press, 1990.Google Scholar
41.Gram, L. F.Inadequate dosing and pharmacokinetic variability as confounding factors in assessment of efficacy of antidepressants. Clinical Neuropharmacology, 1990, 13(suppl. 1), S35–44.CrossRefGoogle ScholarPubMed
42.Greenberg, P. E., Stiglin, L. A., Finkelstein, S. N., & Berndt, E. R.The economic burden of depression in 1990. Journal of Clinical Psychiatry, 1993, 54, 405–18.Google Scholar
43.Guscott, R., & Grof, P.The clinical meaning of refractory depression: A view for the clinician. American Journal of Psychiatry, 1991, 148, 695–704.Google Scholar
44.Guscott, R., & Taylor, L.Lithium prophylaxis in recurrent affective illness: Efficacy, effectiveness and efficiency. British Journal of Psychiatry, 1994, 164, 741–46.CrossRefGoogle ScholarPubMed
45.Hagnell, O., Lanke, J., Rorsman, B., & Öjesjö, L.Are we entering an age of melancholy? Depressive illness in a prospective epidemiological study over 25 years: The Lundby study, Sweden. Psychological Medicine, 1982, 12, 279–89.CrossRefGoogle Scholar
46.Hamilton, M.A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 1960, 23, 56–62.Google Scholar
47.Hatziandreu, E. J., Brown, R. E., Revicki, D. A., et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. PharmacoEconomics, 1994, 5, 249–64.CrossRefGoogle ScholarPubMed
48.Helgasson, T.The epidemiology of depressions. Nordic Journal of Psychiatry, 1990, 44, 3–12.Google Scholar
49.Heninger, G. R., Delgado, P. L., & Charney, D. S.The revised monoamine theory of depression: A modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry, 1996, 29, 2–11.CrossRefGoogle ScholarPubMed
50.Henry, J. A.Debits and credits in the management of depression. British Journal of Psychiatry, 1993, 163(suppl. 20), 33–39.CrossRefGoogle Scholar
51.Henry, J. A.The safety of antidepressants. British Journal of Psychiatry, 1992, 160, 439–41.CrossRefGoogle ScholarPubMed
52.Hollon, S. D., DeRubeis, R. J., Evans, M. D., et al. Cognitive therapy and pharmaco therapy for depression: Singly and in combination. Archives of General Psychiatry, 1992, 49, 774–81.Google Scholar
53.Hyttel, J.Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). International Clinical Psychopharmacology, 1994, 9(suppl. 1), 19–26.Google Scholar
54.Joffe, R. T., & Schuller, D. R.An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depressions. Journal of Clinical Psychiatry, 1993, 54, 269–71.Google Scholar
55.Joffe, R. T., Singer, W., Levitt, A. J., & MacDonald, C.A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Archives of General Psychiatry, 1993, 50, 387–93.Google Scholar
56.Jonsson, B., & Bebbington, P. E.What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. British Journal of Psychiatry, 1994, 164, 665–73.Google Scholar
57.Joyce, P. R., & Paykel, E. S.Predictors of drug response in depression. Archives of General Psychiatry, 1989, 46, 89–99.CrossRefGoogle ScholarPubMed
58.Kallner, G., & Petterson, U.Renal, thyroid and parathyroid function during lithium treatment: Laboratory tests in 207 people treated for 1–30 years. Acta Psychiatrica Scandinavica, 1995, 91, 48–51.Google Scholar
59.Kasper, S.The rationale for long-term antidepressant therapy. International Clinical Psychopharmacology, 1993, 8, 225–35.Google Scholar
60.Katz, M. M., & Maas, J. W.Psychopharmacology and the etiology of psychopathologic states: Are we looking in the right way? Neuropsychopharmacology, 1994, 10, 139–44.Google Scholar
61.Kessler, R. C., McGonagle, K. A., Zhao, S., et al. Life-time and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Archives of General Psychiatry, 1994, 51, 8–19.Google Scholar
62.Kind, P., & Sorensen, J.The costs of depression. International Clinical Psychopharma cology, 1993, 7, 191–95.Google Scholar
63.King, B. H., & Liston, E. H.Proposals for the mechanism of action of convulsive therapy: A synthesis. Biological Psychiatry, 1990, 27, 76–94.Google Scholar
65.Klerman, G. L., & Weissman, M. M.Increasing rates of depression. Journal of the American Medical Association, 1989, 261, 2229–35.CrossRefGoogle ScholarPubMed
66.Kuhn, R.Uber die Behandlung depressiver Zustände mit einem Iminodibenzyl Derivat (G 22355). Schweizehsche Medizinische Wochenschrift, 1957, 87, 1135–40.Google Scholar
67.Kupfer, D. J., Frank, E., Perel, J. M., et al. Five-year outcome for maintenance therapies in recurrent depression. Archives of General Psychiatry, 1992, 49, 769–73.Google Scholar
68.Lam, R. W., Gorman, C. P., Michalon, M., et al. Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. American Journal of Psychiatry, 1995, 152, 1765–70.Google Scholar
69.Lancet. Doubts about the value of maintenance lithium (editorial). Lancet, 1987, i, 424.Google Scholar
70.Lapierre, Y., Bentkover, J., Schainbaum, S., & Manners, S.Direct cost of depression: Analysis of treatment costs of paroxetine versus imipramine in Canada. Canadian Journal of Psychiatry, 1995, 40, 370–77.CrossRefGoogle ScholarPubMed
71.Leibenluft, E., & Wehr, T. A.Is sleep deprivation useful in the treatment of depression? American Journal of Psychiatry, 1991, 149, 159–68.Google Scholar
72.Leonard, B. E.Serotonin receptors: Where are they going? International Clinical Psychopharmacology, 1994, 9(suppl. 1), 7–17.Google Scholar
73.Le Pen, C., Levy, V., Ravily, J. N., et al. The cost of treatment dropout in depression: A cost-benefit analysis of fluoxetine vs. tricyclics. Journal of Affective Disorders, 1994, 31, 1–18.Google Scholar
74.Lesch, K. P., Aulakh, C. S., Wolozin, B. L., et al. Regional brain expression of serotonin transporter messenger RNA and its regulation by reuptake inhibiting antidepressants. Molecular Brain Research, 1993, 17, 31–35.CrossRefGoogle ScholarPubMed
75.Markowitz, J., Brown, R., Sweeney, J., & Mann, J. J.Reduced length and cost of hospital stay for major depression in patients treated with ECT. American Journal of Psychiatry, 1987, 144, 1025–29.Google ScholarPubMed
76.Mårtensson, B., & Aberg-Wistedt, A.Selektiva hämmare av serotoninupptag. Ny grupp antidepressiva ökar i användning. Läkartidningen, 1994, 91, 3371–79.Google Scholar
77.Mårtensson, B., Bartfai, A., Hallén, B., et al. A comparison of propofol and methohexithal as anesthetic agents for ECT: Effects on seizure duration, therapeutic outcome and memory. Biological Psychiatry, 1994, 35, 179–89.CrossRefGoogle Scholar
78.McKenna, S. P., Hunt, S. M., & Tennant, A.Psychological well-being in depressed patients. International Journal of Methods in Psychiatric Research, 1993, 3, 245–51.Google Scholar
79.Medhus, A., Heskestad, S., & Tjemsland, L.Mianserin added to tricyclic antidepressants in depressed patients not responding to an antidepressant alone. Nordic Journal of Psychiatry, 1994, 48, 355–58.Google Scholar
80.Mellerup, E. T., & Plenge, P.The side effects of lithium (editorial). Biological Psychiatry, 1990, 28, 464–66.Google Scholar
81.Merikangas, K. R., Wicki, W., & Angst, J.Heterogeneity of depression: Classification of depressive subtypes by longitudinal course. British Journal of Psychiatry, 1994, 164, 342–48.Google Scholar
82.Meyer, U. A., Amrein, R., Balant, L. P., et al. Antidepressants and drug-metabolizing enzymes: Expert group report. Acta Psychiatrica Scandinavica, 1996, 93, 71–79.Google Scholar
83.Moncrieff, J.Lithium revisited: A re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder (editorial). British Journal of Psychiatry, 1995, 167, 569–74.CrossRefGoogle Scholar
84.Montgomery, S. A., & Asberg, M.A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 1979, 134, 382–89.Google Scholar
85.Montgomery, S. A., & Dunbar, G.Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. International Clinical Psychopharmacology, 1993, 8, 189–95.Google Scholar
86.Montgomery, S. A., Henry, J., McDonald, G., et al. Selective serotonin reuptake inhibitors meta-analysis of discontinuation rates. International Clinical Psychopharmacology 1994, 9, 47–53.Google Scholar
87.Mukherjee, S., Sackeim, H. A., & Schnur, D. B.Electroconvulsive therapy of acute manic episodes: A review of 50 years' experience. American Journal of Psychiatry, 1994, 151, 169–76.Google ScholarPubMed
88.Nierenberg, A. A.The treatment of severe depression: Is there an efficacy gap between SSRI and TCA antidepressant generations? Journal of Clinical Psychiatry, 1994, 55(supp. A), 55–59.Google Scholar
89.NIH Consensus Development Panel on Depression in Late Life. Diagnosis and treatment of depression in late life. Journal of American Medical Association, 1992, 268, 1018–24.Google Scholar
90.Nilsson, B. S.Adverse reactions in connection with zimeldine treatment: A review. Acta Psychiatrica Scandinavica, 1983, 68(suppl. 308), 115–19.Google Scholar
91.Paykel, E. S.Life events, social support and depression. Acta Psychiatrica Scandinavica, 1994, suppl. 377, 50–58.CrossRefGoogle ScholarPubMed
92.Paykel, E. S., Cooper, Z., Ramana, R., & Hayhurst, H.Life events, social support and marital relationships in the outcome of severe depression. Psychological Medicine, 1996, 26, 121–33.Google Scholar
93.Paykel, E. S., & Priest, R. G.Recognition and management of depression in general practice: Consensus statement. British Medical Journal, 1992, 305, 198–202.Google Scholar
94.Peet, M.Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. British Journal of Psychiatry, 1994, 164, 549–50.Google Scholar
95.Phillips, K. A., & Nierenberg, A. A.The assessment and treatment of reactory depression. Journal of Clinical Psychiatry, 1994, 55(suppl. 2), 20–26.Google Scholar
96.Post, R. M., Ketter, T. A., Pazzaglia, P. J., et al. New developments in the use of anticonvulsants as mood stabilizers. Neuropsychobiology, 1993, 27, 132-37.Google Scholar
97.Priest, R. G.Improving the management and knowledge of depression: Marking ‘Defeat of Depression Action Week’ for the Defeat Depression Campaign (editorial). British Journal of Psychiatry, 1994, 164, 285–87.Google Scholar
98.Quitkin, F. M., Stewart, J. W., McGrath, P. J., et al. Columbia atypical depression: A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. British Journal of Psychiatry, 1993, 163(suppl. 21), 30–34.Google Scholar
99.Regier, D. A., Hirshfield, R. M. A., Goodwin, F. K., et al. The NIMH depression awareness, recognition, and treatment program: Structure, aims, and scientific basis. American Journal of Psychiatry, 1988, 145, 1351–57.Google Scholar
100.Revicki, D. A., & Luce, B. R.Methods of pharmacoeconomic evaluations of new medical treatments in psychiatry. Psychopharmacology Bulletin, 1995, 31, 57–65.Google ScholarPubMed
101.Revicki, D. A., Turner, R., Brown, R., & Martindale, J. J.Reliability and validity of a health-related quality of life battery for evaluating outpatient antidepressant treatment. Quality of Life Research, 1992, 1, 257–66.CrossRefGoogle ScholarPubMed
102.Richelson, E.Treatment of acute depression. Psychiatric Clinics of North America, 1993, 16, 461–78.Google Scholar
103.Rifkin, A.ECT versus tricyclic antidepressants in depression: A review of the evidence. Journal of Clinical Psychiatry, 1988, 49, 3–7.Google ScholarPubMed
104.Rorsman, B., Gräsbeck, A., Hagnell, O., et al. A prospective study of first-incidence depression: The Lundby study, 1957–72. British Journal of Psychiatry, 1990, 156, 336–42.Google Scholar
105.Rouillon, F., Phillips, R., Serruier, D., et al. Rechutes de dépression unipolaire efficacité de la maprotiline. L'Encéphale, 1989, 15, 527–34.Google Scholar
107.Sackeim, H. A., Devanand, D. P., & Prudic, J.Stimulus intensity, seizure threshold and seizure duration: Impact on the efficacy and safety of electroconvulsive therapy. Psychiatric Clinics of North America, 1991, 14, 803–42.CrossRefGoogle ScholarPubMed
108.Sackeim, H. A., Prudic, J., & Devanand, D. P. Treatment of medication-resistant depression with electroconvulsive therapy. In Tasman, A., Goldfinger, S., & Kaufmann, C. (eds.), Annual Review of Psychiatry, vol. 9. Washington, DC: American Psychiatric Press, 1990, 91–115.Google Scholar
109.Sackeim, H. A., Prudic, J., Devanand, D. P., et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. New England Journal of Medicine, 1993, 328, 839–46.CrossRefGoogle ScholarPubMed
110.Salzman, C.Dealing with the sexual side effects of SSRI antidepressants. Journal of Practical Psychiatry and Behavioral Health, 1995, 05, 37–39.Google Scholar
111.Scott, J., Eccleston, D., & Boys, R.Can we predict persistence of depression? British Journal of Psychiatry, 1992, 161, 633–37.Google Scholar
112.Simon, G., Ormel, J., VonKorff, M., & Barlow, W.Health care costs associated with depressive and anxiety disorders in primary care. American Journal of Psychiatry, 1995, 152, 352–57.Google Scholar
113.Simon, G. E., VonKorff, M., Ustün, T.B., et al. Is the lifetime risk of depression actually increasing? Journal of Clinical Epidemiology, 1995, 48, 1109–18.Google Scholar
114.Snaith, P.What do depression rating scales measure? British Journal of Psychiatry, 1993, 163, 293–98.Google Scholar
115.Song, F., Freemantle, N., Sheldon, T. A., et al. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability. British Medical Journal, 1993, 306, 683–87.CrossRefGoogle ScholarPubMed
116.Souza, F. G. M., & Goodwin, G. M.Lithium treatment and prophylaxis in unipolar depression: A meta-analysis. British Journal of Psychiatry, 1991, 158, 666–75.Google Scholar
117.Stein, G., & Bernadt, M.Lithium augmentation therapy in tricyclic-resistant depression: A controlled trial using lithium in low and normal doses. British Journal of Psychiatry, 1993, 162, 634–40.Google Scholar
118.Stephens, S. M., Pettinati, H. M., Greenberg, R. M., & Kelly, C. E. Continuation and maintenance therapy with outpatient ECT. In Coffey, C. E. (ed.), The Clinical Science of Electroconvulsive Therapy: Progress in Psychiatry, vol. 38. Washington, DC: American Psychiatric Press, 1993, 143–64.Google Scholar
119.Sternbach, H.The serotonin syndrome. American Journal of Psychiatry, 1991, 148, 705–13.Google Scholar
120.Stoker, M. J., Dunbar, G. C., & Beaumont, G.The SmithKline Beecham ‘quality of life’ scale: A validation and reliability study in patients with affective disorder. Quality of Life Research, 1992, 1, 385–95.CrossRefGoogle Scholar
121.Stokes, P. E.Current issues in the treatment of major depression. Journal of Clinical Psychopharmacology, 1993, 13(suppl. 2), S2–9.Google Scholar
122.Stuppaeck, C., Barnas, C., Schwitzer, J., & Fleischhacker, W. W.The role of carbamazepine in the prophylaxis of unipolar depression. Neuropsychobiology, 1993, 27, 154–57.Google Scholar
123.Surtees, P. G., & Barkley, C.Future imperfect: The long-term outcome of depression. British Journal of Psychiatry, 1994, 164, 327–41.Google Scholar
124.Swartz, C. M.Beyond seizure duration as a measure of treatment quality (editorial). Convulsive Therapy, 1993, 9, 1–7.Google Scholar
125.Thase, M. E., Frank, E., Mallinger, A. G., et al. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. Journal of Clinical Psychiatry, 1992, 53, 5–11.Google Scholar
126.Thies-Flechtner, K., Müller-Oerlinghausen, B., Seibert, W., et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: Data from a randomized prospective trial. Pharmacopsychiatry, 1996, 29, 103–07.Google Scholar
127.Ustün, T. B., & Sartorius, N.Public health aspects of anxiety and depressive disorders. International Clinical Psychopharmacology, 1993, 8(suppl. 1), 15–20.CrossRefGoogle ScholarPubMed
128.Vanselow, W., Dennerstein, L., Armstrong, S., & Lockie, P.Retinopathy and bright light (letter). American Journal of Psychiatry, 1991, 148, 1266–67.Google Scholar
129.Verhoeven, V. M. A., & Tuinier, S.Affective and aggressive behavioral disorders: Thoughts about diagnosis and etiology. New Trends in Experimental and Clinical Psychiatry, 1993, 9, 123–36.Google Scholar
130.Vestergaard, P.Treatment and prevention of mania: A Scandinavian perspective. Neuropsychopharmacology, 1992, 7, 249–59.Google Scholar
131.Wehr, T. A., & Goodwin, F. K.Can antidepressants cause mania and worsen the course of affective illness? American Journal of Psychiatry, 1987, 144, 1403–11.Google ScholarPubMed
132.Weissman, M. M., & Markowitz, J. C.Interpersonal psychotherapy. Current status. Archives of General Psychiatry, 1994, 51, 599–606.Google Scholar
133.Wells, K. B., Rogers, W., Burnam, M. A., & Camp, P.Course of depression in patients with hypertension, myocardial infarction, or insulin-dependent diabetes. American Journal of Psychiatry, 1993, 150, 632–38.Google Scholar
134.Wetterberg, L.Light and biological rhythms. Journal of Internal Medicine, 1994, 235, 5–19.Google Scholar
135.WHO Mental Health Collaborating Centres. Pharmacotherapy of depressive disorders: A consensus statement. Journal of Affective Disorders, 1989, 17, 197–98.Google Scholar
136.Williams, R., Edwards, R. A., Newburn, G. M., et al. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders. International Clinical Psychopharmacology, 1993, 7, 155–58.Google Scholar
137.Zachrisson, O., Mathé, A. A., Stenfors, C., & Lindefors, N.Limbic effects of repeated electroconvulsive stimulation on neuropeptide Y and somatostatin mRNA in the rat brain. Molecular Brain Research, 1995, 31, 71–85.CrossRefGoogle ScholarPubMed
138.Zajecka, J. M., & Fawcett, J.Antidepressant combination and potentiation. Psychiatric Medicine, 1991, 9, 55–75.Google ScholarPubMed
139.Zajecka, J. M., & Fawcett, J.Innovative somatic treatments for depression. Psychiatric Medicine, 1991, 9, 77–103.Google ScholarPubMed